Cargando…
Eculizumab in chemotherapy-induced thrombotic microangiopathy
Thrombotic microangiopathy (TMA) is a rare but severe complication of tumors and their chemotherapeutic treatment. We report on two patients with chemotherapy-induced TMA who were successfully treated with a short course of the terminal complement inhibitor eculizumab. Both patients quickly achieved...
Autores principales: | Schulte-Kemna, Lena, Reister, Barbara, Bettac, Lucas, Ludwig, Ulla, Fürst, Daniel, Mytilineos, Joannis, Bergmann, Carsten, van Erp, Rene, Schröppel, Bernd |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dustri-Verlag Dr. Karl Feistle
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7171698/ https://www.ncbi.nlm.nih.gov/pubmed/32318323 http://dx.doi.org/10.5414/CNCS109836 |
Ejemplares similares
-
Feasibility Analysis of Ultrasound-Guided Placement of Tunneled Hemodialysis Catheters
por: Kächele, Martin, et al.
Publicado: (2023) -
Eculizumab in gemcitabine-induced thrombotic microangiopathy: experience of the French thrombotic microangiopathies reference centre
por: Grall, Maximilien, et al.
Publicado: (2021) -
The use of eculizumab in gemcitabine induced thrombotic microangiopathy
por: Krishnappa, Vinod, et al.
Publicado: (2018) -
The Use of Eculizumab in Tacrolimus-Induced Thrombotic Microangiopathy
por: Gabr, Jihad Ben, et al.
Publicado: (2020) -
Thrombotic microangiopathy and human immunodeficiency virus in the era of eculizumab
por: Jin, Anna, et al.
Publicado: (2016)